Adaptimmune Therapeutics - ADAP Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ADAP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADAP, but not buy additional shares or sell existing shares.
View ADAP analyst ratings or view top-rated stocks.

3 equities research analysts have issued 12 month target prices for Adaptimmune Therapeutics' stock. Their ADAP share price forecasts range from $3.00 to $9.00. On average, they predict the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 142.7% from the stock's current price.
View analysts price targets for ADAP or view top-rated stocks among Wall Street analysts.

Adaptimmune Therapeutics' stock was trading at $3.75 at the beginning of the year. Since then, ADAP shares have decreased by 45.1% and is now trading at $2.06.
View the best growth stocks for 2022 here.

Adaptimmune Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 3,760,000 shares, an increase of 12.6% from the October 31st total of 3,340,000 shares. Based on an average daily volume of 497,900 shares, the days-to-cover ratio is currently 7.6 days. Currently, 2.6% of the shares of the stock are sold short.
View Adaptimmune Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our ADAP earnings forecast.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) released its earnings results on Thursday, November, 4th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.04. The biotechnology company had revenue of $1.20 million for the quarter, compared to the consensus estimate of $1.20 million. Adaptimmune Therapeutics had a negative trailing twelve-month return on equity of 112.16% and a negative net margin of 998.26%. During the same quarter in the previous year, the firm earned ($0.23) earnings per share.

6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP), Micron Technology (MU), BlackRock (BLK), Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG).

(ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

Adaptimmune Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (8.98%), PFM Health Sciences LP (5.69%), Long Focus Capital Management LLC (2.92%), Endurant Capital Management LP (1.09%), BlackRock Inc. (0.86%) and Renaissance Technologies LLC (0.35%). Insiders that own company stock include Adrian Rawcliffe, Elliot Norry, Gavin Wood, James Noble, John Lunger, Lawrence M Alleva, Peter W Sonsini, William C Bertrand Jr and William C Bertrand, Jr.
View institutional ownership trends.

Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADAP stock can currently be purchased for approximately $2.06.

Adaptimmune Therapeutics (NASDAQ:ADAP) has a market capitalization of $337.49 million and generates $6.15 million in revenue each year. The biotechnology company earns $-158,090,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis.

The company employs 494 workers across the globe.

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The official website for the company is www.adaptimmune.com. The biotechnology company can be reached via phone at 441235430000, via email at ir@adaptimmune.com, or via fax at 44-12-3543-0001.